Promising mRNA Vaccine for Pancreatic Cancer Shows 50% Reduction in Recurrence

🧪 Clinical Trial News – July 20, 2025: Promising mRNA Vaccine for Pancreatic Cancer Shows 50% Reduction in Recurrence

Summary: A Phase II clinical trial conducted by BioNTech and Memorial Sloan Kettering Cancer Center reports that a personalized mRNA vaccine for pancreatic cancer has shown a 50% reduction in recurrence among treated patients over 18 months. The trial enrolled 120 participants who had undergone surgery and chemotherapy. Half of them received the new mRNA vaccine tailored to their tumor’s genetic profile.

Clinical Outcome: Patients receiving the vaccine showed strong immune activation with tumor-specific T-cell response. Compared to the control group, recurrence-free survival was significantly longer.

Quote: “This is the first strong evidence that mRNA technology can be adapted beyond infectious disease and used effectively in solid tumor cancer treatment,” said Dr. Luca Cinque, lead oncologist.

Next Step: A Phase III trial is expected to begin by the end of 2025 to further validate efficacy on a larger scale.